ABSTRACTS

O.10 Cardiotoxicity of immune checkpoint inhibitors (ICI): a systematic review and meta-analysis of randomized clinical trials

BJMO - 2021, issue 3, march 2021

Ahmad Hussein Awada , Chris Plummer , Daniel Eiger , Elisa Agostinetto , Evandro de Azambuja , Marcello Ceppi , Marco Bruzzone , Martine Piccart-Gebhart , Matteo Lambertini , Noam Ponde

Introduction: ICI can cause potentially life-threatening adverse events (AE) and their risk of cardiotoxicity has been poorly investigated. It is also unknown whether ICI combinations increases cardiotoxicity compared to single ICI. We aimed to assess the cardiotoxicity rate of ICI compared to other cancer treatments (primary objective) and of dual-agent ICI (immunotherapy combinations) compared to single-agent ICI (secondary objective).

Read more

O.12 Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancer

BJMO - 2021, issue 3, march 2021

Hannah Van Belle , Hans Wildiers

Background: Docetaxel, carboplatin and trastuzumab, with or without pertuzumab (TCH(P)), is increasingly used for (neo) adjuvant treatment of HER2-positive early breast cancer. However, its associated febrile neutropenia (FN) risk is unclear: pivotal studies reported FN risks <10%, but in clinical practice a high FN rate (>20%) was observed. This systematic review and meta-analysis determine the FN risk associated with TCH(P) and the effect of primary prophylactic granulocyte colony-stimulating factor (PP G-CSF).

Read more

O.19 Overall survival improvement in metastatic clear-cell renal cell carcinoma patients from 2000 to 2020

BJMO - 2021, issue 3, march 2021

Annouschka Laenen , Benoit Beuselinck , Eduard Rousse , Hans Wildiers , Herlinde Dumez , Isabel Spriet , Lisa Kinget , Maarten Albersen , Marcella Baldewijns , Patrick Schöffski , Paul M. Clement , Philip R. Debruyne , Sofie Demasure , Wim Wynendaele

Introduction: Only a limited number of recent phase III studies with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs), mTOR-inhibitors or immune checkpoint inhibitors (ICI) in metastatic clear-cell renal cell carcinoma (m-ccRCC) could show an overall survival (OS) benefit compared to standard of care. We aimed to study the evolution of OS of m-ccRCC patients during the last 20-years period (2000–2020).

Read more

O.11 Cyclin dependent kinase inhibitors (CDK4-6i) as adjuvant treatment for patients (pts) with hormone receptor-positive (HR+)/HER2-negative (HER2-) early breast cancer (EBC): a systematic review and meta-analysis

BJMO - 2021, issue 3, march 2021

Elisa Agostinetto , Evandro de Azambuja , Lucas Vian , Marcello Ceppi , Marco Bruzzone , Matteo Lambertini , Noam Ponde , Rafael Caparica

Introduction/aim: The combination of CDK4-6i and endocrine therapy (ET) is standard-of- care for pts with HR+/HER2- advanced breast cancer. However, studies evaluating adjuvant CDK4-6i provided contradictory results thus far. We conducted a systematic review and meta-analysis to assess if the addition of CDK4-6i to adjuvant ET impacts on survival’s outcomes and safety of pts with HR+/HER2- EBC.

Read more

O.13 Colchicine as salvage for refractory pyrexia due to BRAF and MEK inhibitors: a case report

BJMO - 2021, issue 3, march 2021

Anne Hoorens , Celine Jacobs , Ingeborg Hilderson , Michael Saerens

Introduction: Pyrexia is a frequent complication of treatment with BRAF and MEK inhibitors. Management includes a full infectious workup, initiation of paracetamol, NSAIDs, dose interruption and steroids. In rare cases pyrexia is refractory to classic management. Pathogenesis of pyrexia shows similarities with familial mediteranian fever, a disease that usually responds well to colchicine.

Read more

P16 SSB-positive renal cell carcinoma and anti-PD1-induced Sjögren’s syndrome : a key to understand the link between immune-related adverse events and antitumoral activity?

BJMO - 2021, issue 3, march 2021

Dan Truc Nguyen , Soizic Garaud , Stéphane Holbrecht

Introduction: Immune checkpoint inhibitors (ICI) are becoming a cornerstone of therapies for many cancers. However, a new class of side effects has emerged, namely immune-related adverse events (irAEs). Many studies have suggested a potential relationship between irAEs and benefit of ICI, but little is known about the mechanisms underlying toxicity and antitumor efficacy.

Read more

P08 Factors associated with SARS-CoV-2 infection and outcome in patients with solid tumors or hematological malignancies: a single-center study

BJMO - 2021, issue 3, march 2021

Angela Loizidou , Anne-Pascale Meert , Anouk Goudsmit , Chloé Spilleboudt , Edouard Cubilier , Konstantinos Stathopoulos , Philippe Aftimos

Background: Immunocompromised cancer patients are presumed to be at high risk of developing COVID-19 infection. Predisposing factors to contracting COVID-19 and to severe outcomes have been described in registries but were not compared between solid tumors and hematological malignancies.

Read more
X